Experimental approaches for the treatment of malignant gliomas. - Wikidata - wikimedia - TriplyDB

Experimental approaches for the treatment of malignant gliomas.

Experimental approaches for the treatment of malignant gliomas.

http://www.wikidata.org/entity/Q34127138

about

Drug delivery strategies to enhance the permeability of the blood-brain barrier for treatment of glioma Progesterone induces the growth and infiltration of human astrocytoma cells implanted in the cerebral cortex of the rat.Adenoviral vector-mediated gene therapy for gliomas: coming of age.OX26/CTX-conjugated PEGylated liposome as a dual-targeting gene delivery system for brain glioma.Scale to predict survival after surgery for recurrent glioblastoma multiforme Blockade of mTOR signaling via rapamycin combined with immunotherapy augments antiglioma cytotoxic and memory T-cell functions.Synergistic antitumor effect between gefitinib and fractionated irradiation in anaplastic oligodendrogliomas cannot be predicted by the Egfr signaling activity.Major differences between tumor and normal human cell fates after exposure to chemotherapeutic monofunctional alkylator Control of proliferation in astrocytoma cells by the receptor tyrosine kinase/PI3K/AKT signaling axis and the use of PI-103 and TCN as potential anti-astrocytoma therapies.A combined theoretical and in vitro modeling approach for predicting the magnetic capture and retention of magnetic nanoparticles in vivo.Gamma-tocotrienol and hydroxy-chavicol synergistically inhibits growth and induces apoptosis of human glioma cells.SCF, regulated by HIF-1α, promotes pancreatic ductal adenocarcinoma cell progression.Proteomic analysis of glioma chemoresistance.MicroRNA-542-3p Suppresses Tumor Cell Invasion via Targeting AKT Pathway in Human Astrocytoma.YB-1, a new biomarker of glioma progression, is associated with the prognosis of glioma patients.Treatment resistance mechanisms of malignant glioma tumor stem cells The synergic antitumor effects of paclitaxel and temozolomide co-loaded in mPEG-PLGA nanoparticles on glioblastoma cells.Synergistic inhibition of angiogenesis and glioma cell-induced angiogenesis by the combination of temozolomide and enediyne antibiotic lidamycin.Toroidal-spiral particles for codelivery of anti-VEGFR-2 antibody and irinotecan: a potential implant to hinder recurrence of glioblastoma multiforme.Standard of care therapy for malignant glioma and its effect on tumor and stromal cells.Recent advances in brain tumor-targeted nano-drug delivery systems.Animal models for glioma drug discovery.Biogenic gold nanoparticles: As a potential candidate for brain tumor directed drug delivery.Lipoprotein lipase and phospholipid transfer protein overexpression in human glioma cells and their effect on cell growth, apoptosis, and migration.Dihydroartemisinin suppresses glioma proliferation and invasion via inhibition of the ADAM17 pathway.Synergy of enediyne antibiotic lidamycin and temozolomide in suppressing glioma growth with potentiated apoptosis induction.Non-invasive synergistic treatment of brain tumors by targeted chemotherapeutic delivery and amplified focused ultrasound-hyperthermia using magnetic nanographene oxide.Treatment efficacy of DNA lipid nanocapsules and DNA multimodular systems after systemic administration in a human glioma model.Dihydroartemisinin Exerts Anti-Tumor Activity by Inducing Mitochondrion and Endoplasmic Reticulum Apoptosis and Autophagic Cell Death in Human Glioblastoma Cells.L-Carnitine-conjugated nanoparticles to promote permeation across blood-brain barrier and to target glioma cells for drug delivery via the novel organic cation/carnitine transporter OCTN2.Analysis of EGF+61A>G polymorphism and EGF serum levels in Brazilian glioma patients treated with perillyl alcohol-based therapy.

P2860

Q30413487-35CEF42B-12BA-4C89-AC5B-36D516D4517C Q33745937-B403598F-1699-45D6-A4C1-EFE371CAD985 Q34022048-6A89CA50-F682-4D54-97DA-244C6D676C96 Q34062691-4E9D41CF-B804-4B77-A5C6-83CA61764348 Q34131832-CCC8AE9A-6C10-4C50-A043-9184811AF63B Q34647123-9D24EB49-0218-49D6-9FA4-E6E9CE5857B3 Q34848038-F5A13939-D2B8-4767-9806-8AF0B40240AF Q34982828-6D6C5CD2-7C53-4FC1-B928-B50106DFBC9F Q35021348-C6D1BE56-E327-4800-8209-BA2ABC931E35 Q35037158-D8722C21-A63B-4347-B050-50CA8005B286 Q35198623-CCCAF7D9-6F39-4C05-9A0C-F502FC5482D4 Q35208144-382E6650-937A-45E4-833B-75222074ECCA Q35778723-FF566C5E-E72B-45EC-8492-508C65229CBC Q36139783-D744BFE7-4F01-42D9-B2D4-8EA5EC2AAEB6 Q36949616-A0062603-1488-4ED4-AA33-48064B33C041 Q37129807-E1093AA1-F33D-4B31-BBFC-56063838F81A Q37190466-852ECB0B-168F-4D4F-AEC6-501CC90B1203 Q37692451-748B6877-EA40-47DD-8520-B2E5DD5265D3 Q37697047-B6D4662A-B871-45D2-AD1C-A32861451719 Q37930388-F2FF58E8-3565-424C-8D74-3201F1CB1F2C Q38011262-03076705-CC10-4E69-BA7B-9EEC6FD88A9C Q38014575-194E689B-696A-4FE9-B7CE-F758D28E5D7D Q38192664-AEC061AA-6836-4C94-8912-9536EBB169A6 Q38730202-8508AEF5-A349-455C-A040-4E55ED53F84B Q38949261-DE5F897C-0FA5-4C6B-9171-A60FA0C2C267 Q38993557-2F312D22-AA6E-4477-8ECF-7A230563C23B Q39146745-531A8463-2336-4B5D-B57C-693575DF6AEB Q39246483-B416B86A-A79F-4F75-9FCA-6AEC0CBCFA23 Q42369800-34B52903-1BE6-4080-8E10-B95CAB1D0693 Q48035129-3C06F81B-2DD6-48FD-9E33-57AC9B624827 Q48581285-3E8E5F1A-6002-4863-A310-5C5C59B11267

P2860

Experimental approaches for the treatment of malignant gliomas.

http://www.wikidata.org/entity/Q34127138

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Experimental approaches for the treatment of malignant gliomas.

@ast

Experimental approaches for the treatment of malignant gliomas.

@en

Experimental approaches for the treatment of malignant gliomas.

@nl

type

label

Experimental approaches for the treatment of malignant gliomas.

@ast

Experimental approaches for the treatment of malignant gliomas.

@en

Experimental approaches for the treatment of malignant gliomas.

@nl

prefLabel

Experimental approaches for the treatment of malignant gliomas.

@ast

Experimental approaches for the treatment of malignant gliomas.

@en

Experimental approaches for the treatment of malignant gliomas.

@nl

P1433

Q34127138-5B4B9625-4EF4-4397-BFFA-06C7D4A4554A

P1476

Q34127138-0AEBAECC-2AD4-467F-9D1F-FF0E442A03EB

P2093

Q34127138-3620444C-9471-4957-BB12-38F273644BFB

Q34127138-3C9A627D-8C25-4E38-8E79-AC95461D8CBB

Q34127138-45F72F1B-B0D0-4B84-AE82-B3816328A079

Q34127138-61ED6EE6-DC50-4763-8385-AF6D15E7E3E1

Q34127138-F271E725-D861-4DD3-9AA7-B65894451B4B

P2860

Q34127138-00FEFF5E-B24B-4753-8165-943703551A43

Q34127138-014E7742-4E28-458B-BF23-DFE089367937

Q34127138-01DEADB3-DA7E-4165-9BA9-F66B8DC14C0C

Q34127138-0211ADB4-CC96-4B66-926E-32FF730A0EF4

Q34127138-02166C0D-8382-4292-8CC1-30BBD52BEFC1

Q34127138-02D53729-673F-4A05-8A76-D8EF586B3EFF

Q34127138-030C3B7B-F08E-4E93-8482-5CE1409AEE7C

Q34127138-0362F90F-276F-43EC-8E56-9FDD710089FF

Q34127138-0404CB61-C303-4123-AFB4-4196BAF5DC8A

Q34127138-04F0F45D-9CC3-43EA-ACB4-87149B17ED87

P304

Q34127138-E99534EE-9646-48F3-B29B-567C01E6520B

P31

Q34127138-9A0C918E-DEE8-4ABD-AE2E-104C9546BB39

P356

Q34127138-3C28225F-6953-4C52-83B8-E340C2E11110

P433

Q34127138-98F67C61-B32D-4B63-BE0A-89DC931BD604

P478

Q34127138-9D736C97-C52A-4B43-85F0-2D3C45DFEB4E

P577

Q34127138-A64ABB18-90B1-4F05-9F4F-005DD5662E34

P5875

Q34127138-AEB0CD9C-216A-40B1-97C9-5528ADBA5145

P698

Q34127138-9C8E0D1A-49FD-4EC1-A8A7-5A35455A0DB3

P932

Q34127138-B902DDDB-92A6-4A0D-BE0A-69BFB8E85B3B

P356

J.PHARMTHERA.2010.04.015

P1433

Pharmacology & Therapeutics

P1476

Experimental approaches for the treatment of malignant gliomas.

@en

P2093

Grace E Park

http://www.w3.org/2001/XMLSchema#string

Igor Katsyv

http://www.w3.org/2001/XMLSchema#string

John K Park

http://www.w3.org/2001/XMLSchema#string

Leopold Arko

http://www.w3.org/2001/XMLSchema#string

William Patrick Luan

http://www.w3.org/2001/XMLSchema#string

P2860

Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy

First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American society of clinical oncology meeting

Cellular roles of dna topoisomerases: a molecular perspective

Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product

VEGF-Trap: a VEGF blocker with potent antitumor effects.

Small molecule modulation of Smoothened activity

Thalidomide is an inhibitor of angiogenesis

Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

P304

1-36

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.PHARMTHERA.2010.04.015

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

128

http://www.w3.org/2001/XMLSchema#string

P577

2010-06-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44671996

http://www.w3.org/2001/XMLSchema#string

P698

20546782

http://www.w3.org/2001/XMLSchema#string

P932

2939300

http://www.w3.org/2001/XMLSchema#string